Lutetium Dotatate LU-177

→ A decorated GLP-1 pioneer is retiring at Novo Nordisk . Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the building” after 36 years with Novo. Knudsen won the Breakthrough Prize last year with Jens Juul Holst of the Novo Nordisk Foundation Center for Basic Metabolic Research, along with three other scientists, for discovering the peptide that has rocked the industry. She created liraglutide , which is sold as Saxenda for weight loss and Victoza for type 2 diabetes. And while Eli Lilly means business as Novo’s fiercest competitor in the obesity space — adding another approval last week with its GLP-1 pill Foundayo — Ozempic and Wegovy have become household names as Knudsen’s long career draws to a close. “To have played such a pivotal role in advancing science that has meant so much to so many people —that is a privilege beyond measure,” Knudsen wrote. → As it readies itself to release crucial Phase 3 data on its weight loss candidate, Boehringer Ingelheim has lured an obesity specialist away from Novo Nordisk. According to a LinkedIn post , Sylvia Shubert has joined the German drugmaker as SVP of obesity and liver health. She will have much to do in her new role: The American Diabetes Association’s annual meeting in June will see the presentation of data from two late-stage trials of survodutide , the GLP-1 and glucagon agonist that grew out of a 2011 metabolic drug development collaboration between Boehringer and Zealand Pharma . If the data are positive, the company will want to gear up for the shot’s launch in the increasingly competitive obesity space. Before moving to Boehringer, Shubert spent nearly two years at Novo as VP and US therapeutic area head for obesity. She helped oversee the sale of Wegovy, including its launch in new uses — for reducing the risk of cardiovascular events and treating the fatty liver disease MASH. Her experience might come in handy at Boehringer, since survodutide is also in late-stage MASH trials. Earlier, Shubert spent three and a half years at J&J and nearly 14 years at Novartis . → Roche ’s radiotherapy partner Orano Med has tapped Frederic Desdouits as CEO. The Pierre Fabre alum was on the board of directors at TreeFrog Therapeutics before he became CEO of the French stem cell biotech in 2021. Mark Rothera , the former CEO of Orchard Therapeutics , Silence Therapeutics and Viracta Therapeutics , replaced Desdouits at TreeFrog in December. Orano Med also partnered with Sanofi for their radiopharmaceutical AlphaMedix in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Despite encouraging data , Sanofi disclosed in its Q4 update that it deprioritized the asset, opening the door for Perspective Therapeutics to potentially compete with Novartis’ Lutathera . → Dutch ADC developer Byondis has promoted Christoph Korpus to replace Jacques Lemmens as CEO. Lemmens will still chair the board of the company he founded. The new chief executive wrapped up an eight-year tenure with Merck KGaA in December 2024 and became CBO at Byondis in January 2025. Korpus was elevated to director, global business development and licensing oncology at Merck KGaA, a job title he kept for his last three years at the German pharma. → BioCryst has plucked Sandeep Menon from Alnylam and he will lead R&D at the Orladeyo maker, which snapped up another hereditary angioedema candidate when it bought Astria Therapeutics last fall. Menon was chief development officer, head of clinical development and safety for Alnylam, playing a pivotal role in the approval of its heart drug Amvuttra . He held multiple positions over a 13-year career with Pfizer , including CSO, BioMedicine AI and digital sciences. Jon Stonehouse retired from BioCryst on Dec. 31 and handed the reins to commercial chief Charlie Gayer . → Days after Endpoints News exclusively revealed Phase 1b data for Enveda ’s eczema candidate ENV-294 , CEO Viswa Colluru wrote on LinkedIn that Inhwan Kim has been promoted to chief strategy officer. Kim spent the last 18 months as SVP, portfolio strategy & operations. “Three years ago, I came across Enveda in a random late-night LinkedIn post and found its core thesis — to discover novel medicines from life’s chemistry, refined for biological relevance over billions of years of natural R&D — so compelling that I applied on the spot, hoping to be part of the story,” Kim wrote in a separate LinkedIn post . Three years later, Colluru said the new position “formalizes what’s already been true: Inhwan is one of the people who decides what Enveda becomes.” → Peter Anastasiou has been called up from the board of directors to take the COO job at Harmony Biosciences , while Rapport Therapeutics CFO Troy Ignelzi and ex- Sage chairman Geno Germano each nab a spot on the board. Anastasiou has been a board member at Harmony since 2023 and ran Capsida Biotherapeutics from 2022-25 following a 12-year run at Lundbeck . In September, Capsida said a patient died in a trial that was evaluating its gene therapy for a rare brain disorder, and Anastasiou’s LinkedIn page indicates that he left the company a month later. The biotech later revealed in an open letter that the patient died from cerebral edema. Former Acelyrin chief Mina Kim is still listed as interim CEO on Capsida’s website. Harmony also said that Valor Equity Partners ’ Antonio Gracias will step down from the board. → Overcoming a CRL to finally win the first-ever FDA approval for a Barth syndrome treatment, Stealth BioTherapeutics has promoted David Brown to CSO. Few people know the company as well as Brown, who advised Stealth for seven years before joining the team as senior director, scientific and technical innovation in 2019. He moves up to the CSO slot after two years as SVP of discovery. “I am energized by the work we do at Stealth every day to translate deep knowledge of mitochondrial bioenergetics into new medicines for people facing debilitating diseases,” Brown said in a press release . → Norwegian I/O player Lytix Biopharma has selected Novo Nordisk alum Renée Christine Amundsen as COO. Amundsen left Novo last year and was corporate VP for the diabetes commercial unit. Lytix is studying an oncolytic molecule called ruxotemitide as a monotherapy and in combination with Merck ’s Keytruda . → Tenpoint Therapeutics reached the regulatory checkered flag in January with an FDA approval for its presbyopia eye drop Yuvezzi . This week, Tenpoint has welcomed Stephen Lane as CMO. Lane held this position at eye care specialist Alcon , where he was also head of medical safety. When the approval came through, Tenpoint said it hauled in a combined $235 million from an $85 million Series B and a $150 million debt facility. → Joti Marango has landed at Gaithersburg, MD-based Remedy Plan Therapeutics as chief financial and business officer. The former Aptose exec had juggled the roles of COO and CFO at Ikena Oncology , which reverse merged with Inmagene and rebranded to ImageneBio under the ticker $IMA . “With our first oncology study now underway, our differentiated approach to NAMPT inhibition positions us well to tackle increasingly broader segments of the oncology market,” Marango said in a statement . → TuHURA Biosciences , which did a reverse merger of its own with Kintara , has brought in Amanda Garofalo as SVP of clinical operations. The EMD Serono vet also led clinical operations at Parabilis Medicines , a cancer biotech co-founded by Greg Verdine that was once known as FogPharma . After the Kintara agreement, TuHURA then merged with Kineta and picked up a VISTA-inhibiting monoclonal antibody that’s now codenamed TBS-2025 . → Palvella Therapeutics is back for the second time in the last three editions of Peer Review, hiring Kent Taylor as SVP of sales. Taylor had the same responsibilities at Arcutis Biotherapeutics and was VP of sales, dermatology for the inflammation & autoimmunity group at Incyte . We told you that Jennifer McDonough jumped to Palvella last month as SVP of market access and patient services. → Mineralys Therapeutics CEO Jon Congleton has punched his ticket to the board of directors at Avalyn Pharma , the pulmonary fibrosis specialist that filed its S-1 paperwork this week. It’s his second appointment in as many weeks after joining the board at Immunic . → Stoke Therapeutics has added Pfizer veteran Clare Kahn to its board of directors. Kahn has spent the last five years on the board at Solid Biosciences , where Stoke CEO Ian Smith is chairman. Stoke and Biogen are currently testing a Dravet syndrome drug called zorevunersen in a Phase 3 study. → The non-opioid pain experts at Latigo Biotherapeutics have elected Insmed CFO Sara Bonstein to the board of directors. Insmed had a rough go of it this week as the prospects of a label expansion for Brinsupri continue to dim . Meanwhile, Latigo is hoping its Nav1.8 inhibitor can set up a showdown with Vertex ’s Journavx . → Cleveland, OH-based cell and gene therapy maker Abeona Therapeutics has made room for Syndax Pharmaceuticals CFO Keith Goldan on the board of directors. Goldan held the CFO post at Optinose from 2017-22.

CHENGDU, China and JANESVILLE, Wis. , March 26, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, today announced the execution of a Master Radioisotope Supply Agreement with SHINE Technologies, LLC (Janesville, Wisconsin, USA), establishing a long-term, GMP-compliant supply of no-carrier-added lutetium-177 (n.c.a. Lu-177) and granting C-Ray exclusive distribution rights for this critical medical isotope across mainland China — excluding certain pre-existing SHINE partnerships. Under the agreement, C-Ray will serve as SHINE's exclusive distribution partner in mainland China, supplying n.c.a. Lu-177 to Chinese radiopharmaceutical developers, biotechnology companies, and healthcare institutions. C-Ray will leverage its integrated, 28,000-square-meter Chengdu facility to provide downstream services including isotope conjugation, fill-and-finish, and quality control — delivering an end-to-end, ready-to-use isotope solution that substantially lowers the barrier for domestic companies to access internationally benchmarked radioisotope supply. A Critical Isotope, a Strategic Supply Lu-177 is among the most widely used therapeutic radioisotopes in targeted radiopharmaceutical therapy (TRT) globally, with approved and investigational applications across prostate cancer, neuroendocrine tumors (NETs), and a growing range of oncology indications. Its favorable physical half-life, beta emission energy, and co-imaging capability have made it the cornerstone isotope of the RDC field. Supply security has long been a practical constraint on pipeline development in China. This partnership addresses that gap directly: SHINE's Cassiopeia facility — one of North America's largest n.c.a. Lu-177 production sites — will supply C-Ray under terms meeting both Chinese and U.S. regulatory standards, while C-Ray's on-the-ground infrastructure ensures reliable last-mile delivery to clients across mainland China. Leadership Perspectives "This partnership is a significant step in C-Ray's strategic supply diversification. Stable, multi-source isotope access is a core competitive advantage for us and our clients. Building on our leadership in Ac-225 supply, securing a reliable, high-quality source of n.c.a. Lu-177 — along with exclusive distribution rights — directly strengthens our clients' pipeline continuity and reinforces our commitment to building a resilient radiopharmaceutical ecosystem in China. With our integrated platform and deep project management experience, we are confident in our ability to translate premium isotope supply into real patient outcomes and accelerated clinical translation across the industry." — Haitao Qiao, General Manager, C-Ray Therapeutics "We are pleased to partner with C-Ray. This partnership reflects SHINE's ability to serve growing demand for n.c.a. Lu-177 in China while maintaining strong supply for customers in the U.S. and other global markets. By combining C-Ray's integrated development and manufacturing platform with our large-scale isotope production, we can help advance pipeline innovation and expand patient access to life-saving targeted radioligand therapies." — Greg Piefer, Founder and CEO, SHINE Technologies About SHINE Technologies Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy. Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors. Learn more at . About C-Ray Therapeutics C-Ray Therapeutics is a global CRDMO providing end-to-end radiopharmaceutical development services — from target validation and preclinical evaluation to IND-enabling studies, clinical supply, and commercial-scale cGMP manufacturing. Operating from its 28,000-square-meter Chengdu facility under China's Class A Radiation Safety License, C-Ray supports 30+ radioisotopes and has delivered 70+ projects spanning diagnostic and therapeutic programs, including 5 programs at IND or IND-enabling stage, 5 in clinical supply, and 2 in Phase III clinical trials. For more information, visit View original content: SOURCE C Ray Therapeutics